First FDA Cleared Ophthalmic App for Monitoring AMD and DR

Ophthalmic App for Monitoring AMD and DR  has been approved by the FDA and works with an Apple smartphone or iPad.
DALLAS–(BUSINESS WIRE)–Vital Art and Science, LLC (VAS), an emerging ophthalmic medical device company, has introduced the mVT™ Service, an innovative medical device and physician portal that conveniently and accurately tracks the progression of vision damaging diseases such as age related macular degeneration and diabetic retinopathy. The device is available only by prescription and consists of an easily downloaded app that can be used on any Apple smartphone or tablet. Patient test data are automatically uploaded to a Physician’s Portal where licensed eye-care professionals can monitor all patient test results.

“Our clinical trials have confirmed that the results from this convenient home test correlate well with in-office physician assessment and can potentially improve clinical outcomes by bringing in patients for earlier-than-planned examination and possibly treatment”

Age related macular degeneration is the leading cause of blindness for people over 60, and diabetic retinopathy vision loss continues to grow with the increasing prevalence of diabetes. The new mVT™ Service is the only simple, low cost, mobile, validated method available for these patients to test their vision at home. Patients take a simple 4-6 minute self-test, performed on the timetable recommended by the doctor (usually twice a week). The patient’s confidential results are automatically delivered to the Physician Portal for review and analysis.
The mVT™ Service utilizes proven patented proprietary algorithms to assess visual function and detect changes between physician visits. A significant change in the eye condition sends an alert to the doctor who will determine if an earlier intervention is required, such as new appointment, assessment or treatment.
The mVT™ Service, which includes the App and the Physician’s Portal, is available by prescription only and costs patients $8.95/month…..
Read more: http://www.businesswire.com/news/home/20150427005025/en/FDA-Cleared-Ophthalmic-App-Monitoring-AMD-DR#.VT983SFVhBc
Source: Business Wire

On